We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
Read MoreHide Full Article
Goleta, CA-based Inogen Inc. (INGN - Free Report) reported first-quarter 2017 earnings of 27 cents per share, which comfortably beat the Zacks Consensus Estimate and the year-ago figure of 12 cents.
The upside was driven by roughly 22.1% growth in revenues, which totaled $52.5 million, beating the Zacks Consensus Estimate of almost $49.6 million.
Segment Details
Sales revenues surged 40.1% to $46 million, while rental revenues plunged 35.8% to $6.5 million.
Business-to-business: Business-to-business domestic sales were up 84.2% on a year-over-year basis to almost $17.4 million, primarily driven by traditional home medical equipment provider purchases and the consistent strength of the private label partner.
Meanwhile, business-to-business International sales rose around 14.6% to almost $11.4 million on the back of solid demand.
Direct-to-consumer: Direct-to-consumer domestic sales advanced 27.8% to almost $17 million.
However, direct-to-consumer rental sales fell 35.8% to $6.5 million.
Margin Details
In the reported quarter, Inogen registered a gross margin of 49% (as a percentage of revenues), down 50 basis points (bps) on a year-over-year basis.
Meanwhile, sales gross margin expanded 260 bps in the quarter to 52.3%, as a percentage of revenues. Per management, an increase in sales gross margin was driven by lower cost of goods sold in the quarter.
Rental gross margin was 25.9% in the reported quarter, much lower than 48.9% in the first quarter of 2016. This was primarily driven by lower net revenue per rental patient.
Adjusted EBITDA rose 34% to $10.9 million on a year-over-year basis.
Guidance
Inogen reiterated its 2017 revenue and adjusted EBITDA guidance. However, the company raised its full-year adjusted net income guidance.
Inogen projects revenues in the range of $233–$239 million, higher than the previous range of $230–$236 million. This represents year-over-year growth of 14.9%–17.8%. The company expects rental revenue to decline in 2017, courtesy of lower average rental revenue per patient.
Adjusted EBITDA is projected in the band of $46–$50 million, representing an increase of 6%–15.2% year over year.
Inogen expects adjusted net income in the range of $22 million to $24 million, up from the previously provided range of $21–$23 million. This represents 7.2%–17% year-over-year growth.
Our Take
Inogen reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis. In our view, solid domestic and international business-to-business sales has driven the stellar quarterly performance. In fact, the company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe.
However, falling rental revenues raise concern, which might mar the company’s prospects going ahead.
Key Picks
Inogen has a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include Neovasc Inc. , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, Neocasc sports a Zacks Rank #1(Strong Buy), while Hologic and Sunshine Heart carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Neovasc has a solid return of 24.3% for the last three months.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 33.4%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock recorded a stellar EPS growth rate (last 3–5 years of actual earnings) of almost 22%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more.
Image: Bigstock
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
Goleta, CA-based Inogen Inc. (INGN - Free Report) reported first-quarter 2017 earnings of 27 cents per share, which comfortably beat the Zacks Consensus Estimate and the year-ago figure of 12 cents.
The upside was driven by roughly 22.1% growth in revenues, which totaled $52.5 million, beating the Zacks Consensus Estimate of almost $49.6 million.
Segment Details
Sales revenues surged 40.1% to $46 million, while rental revenues plunged 35.8% to $6.5 million.
Business-to-business: Business-to-business domestic sales were up 84.2% on a year-over-year basis to almost $17.4 million, primarily driven by traditional home medical equipment provider purchases and the consistent strength of the private label partner.
Meanwhile, business-to-business International sales rose around 14.6% to almost $11.4 million on the back of solid demand.
Inogen, Inc Price, Consensus and EPS Surprise
Inogen, Inc Price, Consensus and EPS Surprise | Inogen, Inc Quote
Direct-to-consumer: Direct-to-consumer domestic sales advanced 27.8% to almost $17 million.
However, direct-to-consumer rental sales fell 35.8% to $6.5 million.
Margin Details
In the reported quarter, Inogen registered a gross margin of 49% (as a percentage of revenues), down 50 basis points (bps) on a year-over-year basis.
Meanwhile, sales gross margin expanded 260 bps in the quarter to 52.3%, as a percentage of revenues. Per management, an increase in sales gross margin was driven by lower cost of goods sold in the quarter.
Rental gross margin was 25.9% in the reported quarter, much lower than 48.9% in the first quarter of 2016. This was primarily driven by lower net revenue per rental patient.
Adjusted EBITDA rose 34% to $10.9 million on a year-over-year basis.
Guidance
Inogen reiterated its 2017 revenue and adjusted EBITDA guidance. However, the company raised its full-year adjusted net income guidance.
Inogen projects revenues in the range of $233–$239 million, higher than the previous range of $230–$236 million. This represents year-over-year growth of 14.9%–17.8%. The company expects rental revenue to decline in 2017, courtesy of lower average rental revenue per patient.
Adjusted EBITDA is projected in the band of $46–$50 million, representing an increase of 6%–15.2% year over year.
Inogen expects adjusted net income in the range of $22 million to $24 million, up from the previously provided range of $21–$23 million. This represents 7.2%–17% year-over-year growth.
Our Take
Inogen reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis. In our view, solid domestic and international business-to-business sales has driven the stellar quarterly performance. In fact, the company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe.
However, falling rental revenues raise concern, which might mar the company’s prospects going ahead.
Key Picks
Inogen has a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector include Neovasc Inc. , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Notably, Neocasc sports a Zacks Rank #1(Strong Buy), while Hologic and Sunshine Heart carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Neovasc has a solid return of 24.3% for the last three months.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock has a solid one-year return of roughly 33.4%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock recorded a stellar EPS growth rate (last 3–5 years of actual earnings) of almost 22%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more.
Click here for a peek at this private information >>